Literature DB >> 25176592

Novel transcatheter closure of an iatrogenic perimembranous ventricular septal defect.

Elizabeth M Retzer1, Karin E Dill, Atman P Shah.   

Abstract

Iatrogenic membranous ventricular septal defects (VSD) are rare complications of cardiothoracic surgery, most commonly seen as a complication of aortic valve replacements. An iatrogenic VSD can lead to right sided heart failure, systemic hypoxia, and arrhythmias, and closure is often necessary. Given the increased mortality associated with repeat surgical procedures, percutaneous transcatheter closure of these iatrogenic VSDs has increasingly become the preferred choice of therapy. We describe the first case of iatrogenic membranous VSD in the setting of mitral valve replacement and tricuspid valve repair, using the newly approved Amplatzer Duct Occluder II Device from an entirely retrograde approach.
© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  VSD; closure; interventional devices/innovation; structural heart disease intervention

Mesh:

Year:  2014        PMID: 25176592     DOI: 10.1002/ccd.25651

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  3 in total

1.  Acquired aortopulmonary fistula: a case report.

Authors:  Osama Mahmoud; Hadi Elias; Arsalan Rafiq; Amro Alsaid
Journal:  Eur Heart J Case Rep       Date:  2020-07-21

2.  Iatrogenic ventricular septal defect: A rare complication of surgical reconstruction of mitral paravalvular dehiscence.

Authors:  Aref Rashed; Karoly Gombocz; Janos Fulop; Nasri Alotti
Journal:  Int J Surg Case Rep       Date:  2016-08-31

3.  Directly ventricular septal defect closure without using arteriovenous wire loop: Our adult case series using transarterial retrograde approach.

Authors:  Nihat Pekel; Ertuğrul Ercan; Mehmet Emre Özpelit; Ferhat Özyurtlu; Akar Yılmaz; Caner Topaloğlu; Serkan Saygı; Serkan Yakan; İstemihan Tengiz
Journal:  Anatol J Cardiol       Date:  2017-02-21       Impact factor: 1.596

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.